1. |
Aebi S, Karlsson P, Wapnir IL. Locally advanced breast cancer. Breast, 2022, 62 Suppl 1 (Suppl 1): S58-S62. doi: 10.1016/j.breast.2021.12.011.
|
2. |
Huang M, O’Shaughnessy J, Zhao J, et al. Association of pathologic complete response with long-term survival outcomes in triple-negative breast cancer: a meta-analysis. Cancer Res, 2020, 80(24): 5427-5434.
|
3. |
Liu H, Lv L, Gao H, et al. Pathologic complete response and its impact on breast cancer recurrence and patient’s survival after neoadjuvant therapy: a comprehensive meta-analysis. Comput Math Methods Med, 2021, 2021: 7545091. doi: 10.1155/2021/7545091.
|
4. |
Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science, 2011, 331(6024): 1565-1570.
|
5. |
Finisguerra V, Di Conza G, Di Matteo M, et al. MET is required for the recruitment of anti-tumoural neutrophils. Nature, 2015, 522(7556): 349-353.
|
6. |
Wculek SK, Malanchi I. Neutrophils support lung colonization of metastasis-initiating breast cancer cells. Nature, 2015, 528(7582): 413-417.
|
7. |
Li B, Zhou P, Liu Y, et al. Platelet-to-lymphocyte ratio in advanced cancer: review and meta-analysis. Clin Chim Acta, 2018, 483: 48-56.
|
8. |
Liu J, Shi Z, Bai Y, et al. Prognostic significance of systemic immune-inflammation index in triple-negative breast cancer. Cancer Manag Res, 2019, 11: 4471-4480.
|
9. |
Li W, Ma G, Deng Y, et al. Systemic immune-inflammation index is a prognostic factor for breast cancer patients after curative resection. Front Oncol, 2021, 11: 570208. doi: 10.3389/fonc.2021.570208.
|
10. |
Jiang C, Lu Y, Zhang S, et al. Systemic immune-inflammation index is superior to neutrophil to lymphocyte ratio in prognostic assessment of breast cancer patients undergoing neoadjuvant chemotherapy. Biomed Res Int, 2020, 2020: 7961568. doi: 10.1155/2020/7961568.
|
11. |
Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol, 2010, 28(16): 2784-2795.
|
12. |
Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline focused update. J Clin Oncol, 2018, 36(20): 2105-2122.
|
13. |
Giuliano AE, Edge SB, Hortobagyi GN. Eighth edition of the AJCC cancer staging manual: breast cancer. Ann Surg Oncol, 2018, 25(7): 1783-1785.
|
14. |
Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast cancer 2011. Ann Oncol, 2011, 22(8): 1736-1747.
|
15. |
Ogston KN, Miller ID, Payne S, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast, 2003, 12(5): 320-327.
|
16. |
陶苗苗. Ki-67对乳腺癌新辅助化疗pCR预测价值的Meta分析. 重庆: 重庆医科大学, 2018.
|
17. |
Mieog JS, van der Hage JA, van de Velde CJ. Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev, 2007, 2007(2): CD005002. doi: 10.1002/14651858.
|
18. |
Qian X, Xiu M, Li Q, et al. Clinical N3 is an independent risk factor of recurrence for breast cancer patients achieving pathological complete response and near-pathological complete response after neoadjuvant chemotherapy. Front Oncol, 2022, 12: 1019925. doi: 10.3389/fonc.2022.1019925.
|
19. |
Dhanushkodi M, Sridevi V, Shanta V, et al. Locally advanced breast cancer (LABC): real-world outcome of patients from cancer institute, Chennai. JCO Glob Oncol, 2021, 7: 767-781.
|
20. |
Sharma S, Rathore SS, Verma V, et al. Molecular subtypes as emerging predictors of clinicopathological response to neoadjuvant chemotherapy (NACT) in locally advanced breast cancer (LABC): a single-centre experience in Western India. Cureus, 2022, 14(5): e25229. doi: 10.7759/cureus.25229.
|
21. |
Monneur A, Goncalves A, Gilabert M, et al. Similar response profile to neoadjuvant chemotherapy, but different survival, in inflammatory versus locally advanced breast cancers. Oncotarget, 2017, 8(39): 66019-66032.
|
22. |
Reuter S, Gupta SC, Chaturvedi MM, et al. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med, 2010, 49(11): 1603-1616.
|
23. |
Vartolomei MD, Porav-Hodade D, Ferro M, et al. Prognostic role of pretreatment neutrophil-to-lymphocyte ratio (NLR) in patients with non-muscle-invasive bladder cancer (NMIBC): a systematic review and meta-analysis. Urol Oncol, 2018, 36(9): 389-399.
|
24. |
Mandaliya H, Jones M, Oldmeadow C, et al. Prognostic biomarkers in stage Ⅳ non-small cell lung cancer (NSCLC): neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI). Transl Lung Cancer Res, 2019, 8(6): 886-894.
|
25. |
Asano Y, Kashiwagi S, Onoda N, et al. Predictive value of neutrophil/lymphocyte ratio for efficacy of preoperative chemotherapy in triple-negative breast cancer. Ann Surg Oncol, 2016, 23(4): 1104-1110.
|
26. |
Chen Y, Chen K, Xiao X, et al. Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study. BMC Cancer, 2016, 16: 320. doi: 10.1186/s12885-016-2352-8.
|
27. |
Wei B, Yao M, Xing C, et al. The neutrophil lymphocyte ratio is associated with breast cancer prognosis: an updated systematic review and meta-analysis. Onco Targets Ther, 2016, 9: 5567-5575.
|
28. |
Dan J, Tan J, Huang J, et al. The dynamic change of neutrophil to lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients. Breast Cancer, 2020, 27(5): 982-988.
|
29. |
Matowicka-Karna J, Kamocki Z, Polińska B, et al. Platelets and inflammatory markers in patients with gastric cancer. Clin Dev Immunol, 2013, 2013: 401623. doi: 10.1155/2013/401623.
|
30. |
Johnson KE, Ceglowski JR, Roweth HG, et al. Aspirin inhibits platelets from reprogramming breast tumor cells and promoting metastasis. Blood Adv, 2019, 3(2): 198-211.
|
31. |
Cuello-López J, Fidalgo-Zapata A, López-Agudelo L, et al. Platelet-to-lymphocyte ratio as a predictive factor of complete pathologic response to neoadjuvant chemotherapy in breast cancer. PLoS One, 2018, 13(11): e0207224. doi: 10.1371/journal.pone.0207224.
|
32. |
Acikgoz O, Yildiz A, Bilici A, et al. Pretreatment platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio as a predictor of pathological complete response to neoadjuvant chemotherapy in patients with breast cancer: single center experience from Turkey. Anticancer Drugs, 2022, 33(10): 1150-1155.
|
33. |
Zhang M, Huang XZ, Song YX, et al. High platelet-to-lymphocyte ratio predicts poor prognosis and clinicopathological characteristics in patients with breast cancer: a meta-analysis. Biomed Res Int, 2017, 2017: 9503025. doi: 10.1155/2017/9503025.
|
34. |
Krenn-Pilko S, Langsenlehner U, Thurner EM, et al. The elevated preoperative platelet-to-lymphocyte ratio predicts poor prognosis in breast cancer patients. Br J Cancer, 2014, 110(10): 2524-2530.
|
35. |
Ji Y, Wang H. Prognostic prediction of systemic immune-inflammation index for patients with gynecological and breast cancers: a meta-analysis. World J Surg Oncol, 2020, 18(1): 197. doi: 10.1186/s12957-020-01974-w.
|
36. |
Zhang Y, Sun Y, Zhang Q. Prognostic value of the systemic immune-inflammation index in patients with breast cancer: a meta-analysis. Cancer Cell Int, 2020, 20: 224. doi: 10.1186/s12935-020-01308-6.
|
37. |
庞健, 王守满, 廖立秋, 等. 全身免疫炎症指数与三阴性乳腺癌新辅助化疗疗效及预后的相关性. 中南大学学报(医学版), 2021, 46(9): 958-965.
|